SAN DIEGO, Calif., November 1, 2025 – Bloom Science, recognizes Epilepsy Awareness Month and reaffirms its commitment to advancing innovative therapies for individuals living with epilepsy and related neurological disorders.
The company continues to develop novel live biotherapeutic medicines targeting pathways implicated in neurological function.
“Epilepsy Awareness Month is a reminder of the urgent need for improved treatment options,” said Dr. Reyes. “We are driven by science and patient need in our mission to advance meaningful therapeutic innovation.”
About Bloom Science, Inc.
Bloom Science, Inc. is a clinical-stage biotech company focused on the development of novel first-in-class therapies for the treatment of metabolic and neurological disorders. Bloom’s research and development activities leverage its expertise in gut-brain axis biology, metabolism and the microbiome to develop innovative therapeutics designed to improve patients’ lives. Bloom’s clinical programs include BL-001, a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. Bloom Science is advancing a deep pipeline of programs, focused in obesity, Dravet syndrome and DEEs, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.